###begin article-title 0
Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Autosomal dominant optic atrophy (ADOA), a form of progressive bilateral blindness due to loss of retinal ganglion cells and optic nerve deterioration, arises predominantly from mutations in the nuclear gene for the mitochondrial GTPase, OPA1. OPA1 localizes to mitochondrial cristae in the inner membrane where electron transport chain complexes are enriched. While OPA1 has been characterized for its role in mitochondrial cristae structure and organelle fusion, possible effects of OPA1 on mitochondrial function have not been determined.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 270 277 <span type="species:ncbi:9606">patient</span>
Mitochondria from six ADOA patients bearing OPA1 mutations and ten ADOA patients with unidentified gene mutations were studied for respiratory capacity and electron transport complex function. Results suggest that the nuclear DNA mutations that give rise to ADOA in our patient population do not alter mitochondrial electron transport.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
We conclude that the pathophysiology of ADOA likely stems from the role of OPA1 in mitochondrial structure or fusion and not from OPA1 support of oxidative phosphorylation.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 595 600 595 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA4 </italic>
###xml 701 702 701 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 703 704 703 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 867 868 867 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 871 876 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1056 1057 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
Autosomal dominant optic atrophy (ADOA) is a progressive form of bilateral blindness that shares the end-stage clinical characteristics of retinal gangln cell (RGC) death and optic nerve atrophy with the mitochondrial disease, Leber's hereditary optic neuropathy (LHON) [1]. ADOA, also referred to as Kjer's disease (OMIM 165500), has an earlier onset than LHON, with patients presenting mainly during childhood or adolescence. Unlike LHON, which results from mutations in mitochondrial DNA (mtDNA)-encoded complex I subunits, ADOA disease results primarily from mutations in two nuclear genes, OPA1 at 3q28 and OPA4 at 18q12, and displays incomplete penetrance and variable expressivity in families [2-7]. OPA1 mutations are responsible for the majority of reported ADOA cases and nearly half of the reported disease mutations give rise to a truncated OPA1 protein [3]. OPA1 encodes a 960 amino acid mitochondrial dynamin-related GTPase that resides in the inner membrane cristae and plays an essential role in cristae structure and mitochondrial fusion [8-16]. However, the relationship between these roles for OPA1 and the relationship of either function to cellular energy production remain to be elucidated.
###end p 9
###begin p 10
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 443 448 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 624 629 624 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1240 1245 1240 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1358 1363 1358 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1522 1524 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1525 1527 1525 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1528 1530 1528 1530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1531 1533 1531 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1604 1609 1604 1609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 151 158 <span type="species:ncbi:9606">patient</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 1474 1481 <span type="species:ncbi:9606">patient</span>
###xml 1580 1588 <span type="species:ncbi:9606">patients</span>
While OPA1 is critical for optic nerve function, the mechanism by which OPA1 mutations lead to blindness is unknown [1]. A few studies have found ADOA patient OPA1 defects to be associated with diminished ATP synthesis and aberrant mitochondrial architecture at the tissue and cellular level [17-19]. Since cellular structure and nuclear gene expression differs between neurons and most cell types used for analysis of ATP production in ADOA, OPA1 mutations may reduce cellular ATP synthesis by different molecular mechanisms in each cell type [17]. Without an analysis of isolated mitochondria from ADOA patients harboring OPA1 mutations, it remains unclear whether the reduced ATP production in cells arises from a biochemical defect in respiratory function or is secondary to a frank disruption of mitochondrial membrane morphology or mitochondrial biogenesis [17,20,21]. Due to its location in the cristae of the inner membrane, the OPA1 protein may support OXPHOS through interactions with electron transport chain complexes, by maintaining a membrane topology conducive to efficient electron transfer, or by facilitating the fusion of mitochondria into networks that are more responsive to cellular ATP demand. Haploinsufficiency for OPA1 has been suggested as the primary cause of heterozygote phenotypes based on the finding that a downregulation of OPA1 results in cristae disorganization and mitochondrial aggregation, however the level of OPA1 found in some ADOA patient cell lysates was near that of controls [19,20,22,23]. In our study, we examined mitochondria from patients harboring ADOA OPA1 mutations to determine whether the protein defects alter mitochondrial respiration.
###end p 10
###begin p 11
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 685 690 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 846 851 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 916 920 916 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 991 996 991 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1090 1095 1090 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 519 527 <span type="species:ncbi:9606">patients</span>
In a previous publication, we reported seven novel pathological OPA1 mutations in a cohort of 30 patients diagnosed with ADOA [24]. Lymphoblast cell lines were established from blood samples taken from six of the seven patients bearing novel OPA1 disease variants (referred to as OPA1-positive) and from ten ADOA patients without OPA1 mutations (referred to as OPA1-negative) (see Table 1). From these patients, we have isolated and biochemically characterized lymphoblast mitochondria, as was done previously for LHON patients with primary complex I mutations, to determine whether the nuclear DNA mutations give rise to ADOA through defects in OXPHOS [25]. Our findings suggest that OPA1 does not directly contribute to mitochondrial OXPHOS, as neither respiratory capacity nor OXPHOS specific enzyme activity, were affected by the deleterious OPA1 variants. Likewise, mitochondrial function was not diminished in OPA1-negative ADOA lymphoblasts. Based on these findings, we conclude that OPA1 mutations that result in ADOA have indirect effects on ATP production that may correlate with OPA1 function in mitochondrial cristae structure or organelle fusion in RGCs.
###end p 11
###begin p 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
OPA1 mutations in OPA1-positive ADOA patients
###end p 12
###begin p 13
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
aCompound heterozygote.
###end p 13
###begin p 14
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
bResults in a 3 amino acid C-terminal extension.
###end p 14
###begin p 15
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>c</italic></sup>
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
cMutations in OPA1 result in protein truncation at the amino acid shown.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Cell Lines
###end title 17
###begin p 18
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 249 260 <span type="species:ncbi:9606">participant</span>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 811 817 <span type="species:ncbi:9913">bovine</span>
All patients in this study were examined by two experienced neuro-ophthalmologists (NJN, VB) and had clinical symptoms, age of onset, and family histories typical for ADOA, as described previously [24]. Informed consent was obtained from each study participant using an institutional IRB approved consent form. OPA1 exons and intron/exon junctions were sequenced for all patients and a complete characterization of the ADOA-associated OPA1 variants have been described in detail in [24]. None harbored known LHON mtDNA mutations. Lymphoblast cell lines were established by EBV transformation of leukocytes isolated from whole blood by Ficoll-Hypaque gradient [25]. Lymphoblastoid cell lines were maintained in RPMI 1640 medium (Bio-Whitaker, Walkersville, MD) supplemented with 15% (v/v) heat-inactivated fetal bovine serum (Life Technologies, Inc., Grand Isle, NY).
###end p 18
###begin title 19
Mitochondrial Isolation, Polarography, and Enzymology
###end title 19
###begin p 20
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
All procedures for mitochondrial isolation, polarographic respiration analysis and respiratory chain enzymology have been previously described [25-27]. Briefly, for respiration studies, electrons were entered at either complex I (using either malate + pyruvate or glutamate + malate as substrate) or complex II (using succinate as the substrate) using intact whole mitochondria. Two polarographic runs were performed for each substrate and each run included two additions of ADP (125 nmole for complex I substrates and 75 nmole for succinate) to stimulate state III and subsequent state IV respiration. Each run was concluded by the addition of the OXPHOS uncoupler, 2,4-dinitrophenol (DNP) to assess maximal respiration rates. All runs were performed with 250 - 500 mug of mitochondrial protein.
###end p 20
###begin p 21
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
OXPHOS specific enzyme activities in submitochondrial particles were measured using a Varian Cary 300 Bio UV/Vis spectrophotometer [25-27]. Briefly, mitochondrial protein was prepared by sonication of isolated organelles. Complex I activity was monitored in triplicate samples as the reduction of 10 muM decylubiquinone at 272 nm by 30 mug of mitochondrial protein with 30 muM NADH. Using this method, 90-100% of the total complex I activity is sensitive to rotenone inhibition. Complex III and complex IV activities were determined at 550 nm in duplicate samples containing 7.5 mug mitochondrial protein and appropriate substrates. Complex III activity was assayed as the antimycin A-sensitive oxidation of reduced decylubiquinone by cytochrome c. Using this method, complex III activity is 75 - 100% antimycin A sensitive. Complex IV activity was determined by the cyanide-sensitive oxidation of cytochrome c. Citrate synthase was assayed at 412 nm in duplicate samples containing 15 mug of mitochondrial protein.
###end p 21
###begin p 22
###xml 429 443 427 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">data not shown</italic>
###xml 446 448 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 449 451 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 493 495 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 596 598 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 599 601 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
For all samples, mitochondrial protein concentration was determined using the modified Lowry assay and mitochondrial preparations were not used for biochemical analysis if the protein concentration was below 2 mg/ml. Further, all mitochondrial preparations exhibited a respiratory control ratio of >/= 4, indicative of a high quality mitochondrial isolation as evidenced by well-coupled mitochondria upon polarographic analysis (data not shown) [25,28]. Statistical significance for all data (p < 0.05) was determined by the Mann-Whitney unpaired, two-tailed test using Instat Graphpad Software [25,29].
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 456 460 456 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 776 780 776 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 1207 1211 1207 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 1686 1700 1686 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">data not shown</italic>
###xml 1755 1759 1755 1759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 213 220 <span type="species:ncbi:9606">patient</span>
###xml 470 477 <span type="species:ncbi:9606">patient</span>
###xml 795 802 <span type="species:ncbi:9606">patient</span>
###xml 848 855 <span type="species:ncbi:9606">patient</span>
###xml 1067 1074 <span type="species:ncbi:9606">patient</span>
###xml 1221 1229 <span type="species:ncbi:9606">patients</span>
###xml 1501 1508 <span type="species:ncbi:9606">patient</span>
###xml 1611 1619 <span type="species:ncbi:9606">patients</span>
###xml 1787 1794 <span type="species:ncbi:9606">patient</span>
To assess mitochondrial function in ADOA patients, we determined mitochondrial respiratory function and respiratory chain enzyme specific activities in both OPA1-positive and OPA1-negative ADOA patients. For each patient cohort, both complex I-linked (malate + pyruvate and glutamate + malate substrates) and complex II-linked (succinate) maximal (state III) respiration rates were not significantly diminished relative to the control group (Table 2). For OPA1-positive patient mitochondria, only slight reductions in all complex I rates (ranging from 1-12%) were found when comparing the average rates from both complex I-linked substrates with the controls. These data suggest that OPA1 has no direct role in OXPHOS, however individual variation in OXPHOS exists within the OPA1-positive ADOA patient mitochondria. For example, mitochondria from patient P3 showed elevations in all respiration rates when entering electrons at complex I and complex II, and P6 mitochondria displayed a notable decrease in rates with all substrates. Although the data for individual patient mitochondria are insignificant due to sample size, results for P3 and P6 mutations suggest that further study may be warranted. For OPA1-negative patients, respiratory rate reductions were observed with complex I-linked substrates (ranging from 11-18%) and succinate (ranging from 15-20%), however these differences from the controls were not statistically significant. RCR values from polarography analysis revealed that all patient and control mitochondria were well-coupled, and ADP/O ratios showed no statistical difference between patients and controls for both complex I and complex II-linked substrates (data not shown). Overall, we could not detect respiration defects in OPA1-positive or -negative ADOA patient mitochondria.
###end p 24
###begin p 25
###xml 31 38 <span type="species:ncbi:9606">patient</span>
Polarographic analysis of ADOA patient and control mitochondria
###end p 25
###begin p 26
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
aAbbreviations used for respiratory rate data are III, state III rate; IV, state IV rate; and UC, uncoupled rate.
###end p 26
###begin p 27
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 24 31 <span type="species:ncbi:9606">patient</span>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
bAbbreviations used for patient genetics are OPA1+, OPA1-positive patients and OPA1-,OPA1-negative patients
###end p 27
###begin p 28
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 596 600 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 768 772 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 934 939 934 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1064 1068 1064 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 1152 1153 1152 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 111 118 <span type="species:ncbi:9606">patient</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
###xml 782 790 <span type="species:ncbi:9606">patients</span>
###xml 1017 1025 <span type="species:ncbi:9606">patients</span>
###xml 1078 1086 <span type="species:ncbi:9606">patients</span>
###xml 1164 1172 <span type="species:ncbi:9606">patients</span>
Mitochondrial respiratory chain enzyme specific activities were assayed in submitochondrial particles for both patient groups (Table 3). Complexes I, III, IV, and the mitochondrial matrix enzyme citrate synthase (CS) were studied, with CS activity used for normalization of the respiratory chain enzyme activities. We found that complex I activity was reduced by 10.6% in OPA1-positive patients relative to controls, but this reduction was not statistically significant. The apparent reduction in complex I activity also was evident when complex I activities were normalized to CS activities, as OPA1-positive patients had a complex I/CS ratio of 0.11 while controls demonstrated a normalized ratio of 0.13. Thus, normalized complex I activities were still reduced in OPA1-positive patients, but by a modest 15%. Given the variability in the raw and CS normalized complex I activities, it remains possible that individual deleterious OPA1 mutations may impact OXPHOS and a careful analysis of a greater population of patients with of these mutations is needed. In OPA1-negative patients, complex I activity was essentially identical to controls (Table 3). For all patients, complex III and IV activities were very similar to the control activities.
###end p 28
###begin p 29
###xml 33 40 <span type="species:ncbi:9606">patient</span>
Specific enzyme analysis of ADOA patient and control mitochondria
###end p 29
###begin p 30
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
aAbbreviations used above are CS, citrate synthase, OPA1+, OPA1-positive patients, and OPA1-, OPA1-negative patients
###end p 30
###begin p 31
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 771 775 771 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 900 904 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 987 992 987 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
###xml 504 511 <span type="species:ncbi:9606">patient</span>
###xml 785 792 <span type="species:ncbi:9606">patient</span>
###xml 914 922 <span type="species:ncbi:9606">patients</span>
For our OPA1-positive patients, two (P2 and P3) harbored pathogenic missense mutations and four (P4, P6-8) contained protein-truncating variants (Table 1). Since the protein terminating mutations may be considered potentially more severe than the missense mutations, we examined our data to see if this was the case from a functional perspective. Although our sample size is low, we found no significant differences between OPA1-positive patients with missense or frameshift/nonsense mutations. Further, patient P2 is a compound heterozygote, harboring both the c.239A>G exon 2 missense mutation and the c.2883A>C exon 28 variant that changes the OPA1 stop codon to a tyrosine and extends the OPA1 polypeptide 3 additional amino acids. As indicated in Tables 2 and 3 for OPA1-positive patient P2, both respiration and specific enzyme activities do not differ significantly when compared to the other OPA1-positive patients, suggesting that the combined presence of these two deleterious OPA1 variants does not cause greater functional impairment.
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 224 233 224 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 437 441 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 454 458 454 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 25 32 <span type="species:ncbi:9606">patient</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 745 753 <span type="species:ncbi:9606">patients</span>
The analysis of six ADOA patient lymphoblastoid cell lines with mutations in the nuclear gene OPA1 indicates that OPA1 has no direct role in mitochondrial respiratory chain function. These data represent the first report on in vitro OXPHOS function using isolated mitochondria from patients with ADOA. No significant effects on respiratory capacity or specific electron transport chain enzyme activity were observed in mitochondria from OPA1-positive or OPA1-negative ADOA patients suggesting that ADOA-related gene defects alter mitochondrial function primarily by disruption of inner mitochondrial membrane topography. This is intriguing as the bilateral vision loss experienced by ADOA patients is clinically similar to that observed in LHON patients harboring primary complex I mtDNA variants that directly impair mitochondrial biochemistry [25,28]. Overall, it appears that RGC function is sensitive to different mechanisms of mitochondrial perturbation.
###end p 33
###begin p 34
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 548 549 548 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 555 560 555 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 768 773 768 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 819 820 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 847 852 847 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1112 1114 1112 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1115 1117 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1284 1289 1284 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1437 1439 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
###xml 230 237 <span type="species:ncbi:9606">patient</span>
###xml 377 382 <span type="species:ncbi:9606">human</span>
###xml 674 681 <span type="species:ncbi:9606">patient</span>
The study of OPA1 in the physiological context of ADOA is limited by the inability to culture patient RGCs. Similar to previous studies of LHON complex I mutations, our study of mitochondrial respiratory capacity of isolated ADOA patient organelles was an attempt to elucidate the pathological role of OPA1 at the biochemical level and enhance knowledge gained through several human cell models [17-19]. OPA1 is expressed as eight, tissue-specific transcripts resulting from alternative splicing in the gene region encompassing exons 4 through 5b [8,13]. OPA1 transcripts 1, 4 and 7 expressed in retina are also found in leukocytes, therefore the results obtained here with patient lymphoblast mitochondria should reflect any mitochondrial impairments due to the ADOA OPA1 mutations affecting protein isoforms in RGCs [8]. The protein products of OPA1 transcripts 1, 2, 4 and 7 support mitochondrial fusion activity to a greater extent than other OPA1 isoforms [30]. The OPA1 protein encoded by each transcript is cleaved by proteases within the mitochondrial matrix at sequences translated from exons 5 and 5b [13,30,31]. This activity removes the N-terminal, membrane-anchored region of the full-length protein generating one or more short, matrix isoforms. Both the long and short OPA1 gene products are required for mitochondrial fusion activity, and proteolysis is in part stimulated by loss of mitochondrial membrane potential [13,30].
###end p 34
###begin p 35
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 857 862 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1027 1032 1027 1032 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1220 1225 1220 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 31 38 <span type="species:ncbi:9606">patient</span>
The ADOA OPA1 mutations in our patient lymphoblasts alter key functional domains that are present in all OPA1 proteins and lie outside of the proteolytic sites of the OPA1 protein (Table 1). The mutations would affect both long and short isoforms and should disrupt OPA1-mediated networking of mitochondria that may be required for the high level of ATP production in RGCs [3,8-10,12,13,15,16,19,30]. Surprisingly, none of the OPA1 mutations evaluated here diminished OXPHOS to a significant extent, even though the c.2708delTTAG mutation has been associated with decreased ATP synthesis in fibroblasts and OPA1 appears to interact with AIF, a stability factor for electron transport chain complex I [19]. Although ADOA shares many clinical hallmarks of LHON, defects in OPA1 do not compromise mitochondrial respiratory capacity. These results suggest that OPA1 may not be required for maintaining the electron transport chain for OXPHOS and may function primarily at the level of mitochondrial morphology within RGCs. Indeed, OPA1 function in the control of morphology may require alterations in membrane potential or cellular signals not induced in the context of cell culture, thereby limiting our ability to observe OPA1 effects in isolated mitochondria.
###end p 35
###begin p 36
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 1068 1073 1068 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 1600 1604 1600 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1</italic>
###xml 1944 1946 1944 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1947 1949 1947 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1950 1952 1950 1952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 469 476 <span type="species:ncbi:9606">patient</span>
###xml 484 491 <span type="species:ncbi:9606">patient</span>
###xml 496 503 <span type="species:ncbi:9606">Patient</span>
###xml 1085 1092 <span type="species:ncbi:9606">patient</span>
A recent report by Schimpf et al. suggests that OPA1 mutations that would produce large C-terminal truncations in OPA1 protein may lead to message degradation by nonsense mediated mRNA decay (NMD) [32,33]. The net effect of NMD would be expression of protein only from the functional OPA1 allele, thereby creating a haploinsufficiency for OPA1. This mechanism may be the underlying cause of RGC death and disease in our OPA1-positive ADOA patients with two exceptions, patient P2 and patient P3. Patient P2 is a compound heterozygote harboring two mutant alleles, a mitochondrial targeting sequence mutation in exon 2 and a Stop961Tyr in exon 28, which extends the C-terminus by 3 amino acids. The exon 2 mutation should prevent mitochondrial localization of the gene product, resulting in a downregulation of functional protein expression and haploinsufficiency. The three amino acid extension of OPA1 is not expected to alter protein function, however a small effect on protein activity may be detrimental in the context of diminished levels mitochondrial OPA1. The OPA1 genotype of patient P3 is more intriguing, as the single base change results in an amino acid substitution, Tyr841Cys, that lies outside of known functional domains in the C-terminal region. The Tyr841Cys OPA1 protein should be expressed and targeted to the mitochondria where it conceivably may compete in molecular interactions with both the long and short isoforms of protein expressed from the normal allele. While no significance was found for the average mitochondrial respiration and specific activity data for the ADOA OPA1-positive mitochondria compared to controls, mitochondria from P3 lymphoblasts displayed notably higher respiration, slightly elevated complex I activity, and substantially lower complex IV activity. This suggests that the Tyr841 may mediate regulatory or stabilizing interactions with complexes I and IV within the mitochondrial membrane [18,19,34]. A more detailed analysis of the C-terminus of OPA1 may uncover critical interactions with the electron transport chain in the cristae of the mitochondria.
###end p 36
###begin title 37
Conclusion
###end title 37
###begin p 38
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
###xml 124 129 124 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPA1 </italic>
From this study we conclude that OPA1 is not directly involved in maintaining electron transport efficiency for OXPHOS. The OPA1 mutations causing ADOA most likely result in a cellular haploinsufficiency for OPA1 protein in mitochondrial network formation and total cellular energy production. The results obtained for mitochondria bearing an OPA1 protein with a Tyr841Cys change in the C-terminus indicate that this domain of OPA1 could be responsible for stabilizing electron transport chain complexes and suggest that functional interactions for OPA1 may exist within the inner membrane. However, the apparent cause of ADOA pathology is the loss of OPA1 control of mitochondrial morphology in RGCs.
###end p 38
###begin title 39
Authors' contributions
###end title 39
###begin p 40
###xml 30 37 <span type="species:ncbi:9606">patient</span>
###xml 206 213 <span type="species:ncbi:9606">patient</span>
###xml 303 311 <span type="species:ncbi:9606">patients</span>
###xml 328 335 <span type="species:ncbi:9606">patient</span>
VM isolated mitochondria from patient lymphoblasts, conducted all respiration and enzymology experiments, and performed data analysis. AL isolated DNA and prepared EBV-transformed lymphoblastoid lines from patient blood samples and maintained cell lines for mitochondrial isolation. VB and NN diagnosed patients and facilitated patient enrollment and collection of blood samples in accordance with the institutional IRB informed consent. SC performed statistical analysis and drafted and revised the manuscript. MB designed the study, supervised all data collection and analysis, and assisted in manuscript preparation. All authors read and approved submission of the final manuscript.
###end p 40
###begin title 41
Acknowledgements
###end title 41
###begin p 42
###xml 13 21 <span type="species:ncbi:9606">patients</span>
We thank the patients and their families for their contributions, the National Eye Institute for support through grant award EY014393 (M.D.B./S.D.C.), and Research to Prevent Blindness (New York, NY) for an unrestricted grant to the Emory University School of Medicine Department of Ophthalmology.
###end p 42
###begin article-title 43
Mitochondrial Optic Neuropathies: How Two Genomes may Kill the Same Cell Type?
###end article-title 43
###begin article-title 44
Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy
###end article-title 44
###begin article-title 45
eOPA1: an online database for OPA1 mutations
###end article-title 45
###begin article-title 46
Spectrum, frequency and penetrance of OPA1 mutations in dominant optic atrophy
###end article-title 46
###begin article-title 47
###xml 18 26 <span type="species:ncbi:9606">patients</span>
OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance
###end article-title 47
###begin article-title 48
###xml 56 64 <span type="species:ncbi:9606">patients</span>
A comprehensive survey of mutations in the OPA1 gene in patients with autosomal dominant optic atrophy
###end article-title 48
###begin article-title 49
Dominant optic atrophy: correlation between clinical and molecular genetic studies
###end article-title 49
###begin article-title 50
Mutation spectrum and splicing variants in the OPA1 gene
###end article-title 50
###begin article-title 51
OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28
###end article-title 51
###begin article-title 52
OPA1 requires mitofusin 1 to promote mitochondrial fusion
###end article-title 52
###begin article-title 53
Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis
###end article-title 53
###begin article-title 54
Emerging functions of mammalian mitochondrial fusion and fission
###end article-title 54
###begin article-title 55
Regulation of mitochondrial morphology through proteolytic cleavage of OPA1
###end article-title 55
###begin article-title 56
Mitochondrial inner-membrane fusion and crista maintenance requires the dynamin-related GTPase Mgm1
###end article-title 56
###begin article-title 57
Dissecting mitochondrial fusion
###end article-title 57
###begin article-title 58
The machines that divide and fuse mitochondria
###end article-title 58
###begin article-title 59
Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy
###end article-title 59
###begin article-title 60
OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes
###end article-title 60
###begin article-title 61
OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion
###end article-title 61
###begin article-title 62
Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis
###end article-title 62
###begin article-title 63
Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria
###end article-title 63
###begin article-title 64
The many shapes of mitochondrial membranes
###end article-title 64
###begin article-title 65
Expression of the Opa1 mitochondrial protein in retinal ganglion cells: its downregulation causes aggregation of the mitochondrial network
###end article-title 65
###begin article-title 66
OPA1 mutations and mitochondrial DNA haplotypes in autosomal dominant optic atrophy
###end article-title 66
###begin article-title 67
Functional analysis of lymphoblast and cybrid mitochondria containing the 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation
###end article-title 67
###begin article-title 68
###xml 57 64 <span type="species:ncbi:9606">patient</span>
Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines
###end article-title 68
###begin article-title 69
The role of mtDNA background in disease expression: a new primary LHON mutation associated with Western Eurasian haplogroup J
###end article-title 69
###begin article-title 70
Clinical, genetic, and biochemical characterization of a Leber hereditary optic neuropathy family containing both the 11778 and 14484 primary mutations
###end article-title 70
###begin article-title 71
Use of transmitochondrial cybrids to assign a complex I defect to the mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene mutation at nucleotide pair 14459 that causes Leber hereditary optic neuropathy and dystonia
###end article-title 71
###begin article-title 72
OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L
###end article-title 72
###begin article-title 73
OPA1 and PARL keep a lid on apoptosis
###end article-title 73
###begin article-title 74
Nonsense-mediated mRNA decay in health and disease
###end article-title 74
###begin article-title 75
Comprehensive cDNA study and quantitative transcript analysis of mutant OPA1 transcripts containing premature termination codons
###end article-title 75
###begin article-title 76
Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane
###end article-title 76

